title: Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
abstract: This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 months, chelation was associated with longer median overall survival (52.2 months vs. 104.4 months; p<.0001) and a trend toward longer leukemia-free survival and fewer cardiac events. No differences in safety were apparent between groups. Limitations of this analysis included, varying time from diagnosis and duration of chelation, and the fact that the decision to chelate may have been influenced by pt clinical status.
authors: Cancer Care Centers of South Texas, San Antonio, TX, USA; US Oncology, The Woodlands, TX, USA. Electronic address: roger.lyons@usoncology.com.
authors: Roger M
authors: RM
authors: Lyons
authors: US Oncology, The Woodlands, TX, USA; Texas Oncology-South Texas Cancer Center, McAllen, TX, USA.
authors: Billie J
authors: BJ
authors: Marek
authors: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors: Carole
authors: C
authors: Paley
authors: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors: Jason
authors: J
authors: Esposito
authors: US Oncology, The Woodlands, TX, USA; New York Oncology Hematology, P.C., Albany, NY, USA.
authors: Lawrence
authors: L
authors: Garbo
authors: US Oncology, The Woodlands, TX, USA; Rocky Mountain Cancer Centers, Aurora, CO, USA.
authors: Nicholas
authors: N
authors: DiBella
authors: University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
authors: Guillermo
authors: G
authors: Garcia-Manero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015913:Chelation Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000453:epidemiology*; D011446:Prospective Studies; D012042:Registries; D012306:Risk; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007502:Iron Chelating Agents
keywords: Chelation; Ferritin; Iron overload; Leukemia; Myelodysplastic syndrome; Survival